Caladrius Biosciences Inc Stock Nasdaq
Equities
US1280581042
Biotechnology & Medical Research
End-of-day quote
Other stock markets
|
||
- USD | - |
05-09 | Transcript : Lisata Therapeutics, Inc., Q1 2024 Earnings Call, May 09, 2024 | |
05-09 | Lisata Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
Sales 2024 * | - | Sales 2025 * | - | Capitalization | 24.59M 33.55M |
---|---|---|---|---|---|
Net income 2024 * | -25M -34.11M | Net income 2025 * | -30M -40.93M | EV / Sales 2024 * | - |
Net cash position 2024 * | - 0 | Net cash position 2025 * | - 0 | EV / Sales 2025 * | - |
P/E ratio 2024 * |
-0.96
x | P/E ratio 2025 * |
-1.1
x | Employees | - |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 81.21% |
Latest transcript on Caladrius Biosciences Inc
1st Jan change | Capi. | |
---|---|---|
+29.03% | 48.16B | |
-0.10% | 41.73B | |
+43.45% | 41.03B | |
-5.26% | 28.77B | |
+11.48% | 25.59B | |
-22.74% | 18.96B | |
+9.06% | 12.92B | |
+30.01% | 12.03B | |
-1.51% | 11.77B |